Glaxo CEO Expects Profit to Rise, Prepares for Split

The transcript discusses GSK's financial outlook, highlighting a 12-14% growth in earnings from its pharma and vaccines business. It outlines the company's R&D pipeline, with 64 assets and significant milestones in various medical fields. The discussion also covers the impact of the pandemic on oncology and healthcare, GSK's strategic shift towards vaccines and specialty medicines, and the company's plans to demerge into two entities. The focus on creating shareholder value and addressing concerns from Elliott Management is emphasized, with a commitment to future growth and innovation.

What is the expected top-line growth rate for GSK's pharma business in 2022?

• 10 to 12%

• 8 to 10%

• 5 to 7%

• 3 to 5%

Which area of healthcare has GSK reinvested in, as mentioned in the second section?

• Cardiology

• Oncology

• Neurology

• Dermatology

What was the reason for GSK rejecting Unilever's bid?

• Lack of interest in the consumer business

• Unilever's bid undervalued GSK's consumer business

• Regulatory issues

• GSK's focus on pharmaceuticals

What is GSK's primary focus in terms of shareholder value?

• Reducing operational costs

• Expanding into new markets

• Creating shareholder value

• Increasing market share

What has been a significant challenge for GSK's CEO over the past five years?

• Regulatory hurdles

• Negative stock returns

• Increasing competition

• Supply chain issues

What transformation has GSK undergone in the past four years?

• Acquisition of smaller companies

• Reduction in workforce

• Wholesale transformation of investment in R&D

• Expansion into new markets

What is the expected bottom-line growth for GSK in the coming year?

• Triple-digit growth

• Double-digit growth

• Single-digit growth

• No growth